AI assistant
Sending…
Forte Biosciences, Inc. — Director's Dealing 2017
May 31, 2017
33769_dirs_2017-05-31_20c800a0-d310-42da-9a10-45bace6e6820.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Tocagen Inc (TOCA)
CIK: 0001419041
Period of Report: 2017-05-26
Reporting Person: GRUBER HARRY E (Director, President, Research & Devel)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-05-26 | Employee Stock Option (right to buy) | $16.32 | A | 40000 | Acquired | 2027-05-25 | Common Stock (40000) | Direct |
Footnotes
F1: 1/4th of the shares vest one year after 5/26/2017; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of 5/26/2017.
More from Forte Biosciences, Inc.
Regulatory Filings
2026
Jun 2
Share Issue/Capital Change
2026
Jun 2
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 2
Earnings Release
2026
May 14
Capital/Financing Update
2026
Apr 9
Capital/Financing Update
2026
Apr 9
Capital/Financing Update
2026
Apr 8
Regulatory Filings
2026
Apr 1
Major Shareholding Notification
2026
Jan 29
Major Shareholding Notification
2026
Jan 20